[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363479-105":59,"doc-detail-363479-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","prevalence-and-determinants-of-polypharmacy-among-cancer-patients-a-systematic-review-and-meta-analysis","Prevalence and determinants of polypharmacy among cancer patients - a systematic review and meta-analysis","","Polypharmacy (PP) is a growing clinical challenge for people diagnosed with cancer, yet its true burden, prevalence estimates, and definitions across studies remain uncertain. A systematic search of PubMed, EMBASE, Scopus, CDSR, and Google Scholar (2000–2025) evaluated eligible studies on PP in cancer patients. The review pooled prevalence overall and by cancer type, including rates of potentially inappropriate medications and drug–drug interactions, and assessed heterogeneity using I2.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prevalence-and-determinants-of-polypharmacy-among-cancer-patients-a-systematic-review-and-meta-analysis/363479/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prevalence-and-determinants-of-polypharmacy-among-cancer-patients-a-systematic-review-and-meta-analysis/363479.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",18,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What does the study aim to determine about polypharmacy in cancer patients?","Question",{"text":113,"@type":114},"It estimates the overall prevalence of polypharmacy, explores prevalence by type of cancer, and evaluates related patterns such as potentially inappropriate medications and drug–drug interactions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which databases and time period were searched?",{"text":118,"@type":114},"PubMed, EMBASE, Scopus, CDSR, and Google Scholar were searched for studies published between 2000 and 2025.",{"name":120,"@type":111,"acceptedAnswer":121},"What prevalence range was found across the included studies?",{"text":122,"@type":114},"The pooled prevalence was 29% (95% CI 10–52%) under the quality effects model and 58% (95% CI 50–62%) under the random effects model, with substantial heterogeneity reported (I2 = 100%).",{"name":124,"@type":111,"acceptedAnswer":125},"Why does the study emphasize further research?",{"text":126,"@type":114},"Marked variability and high heterogeneity indicate the need for future prospective and systematic studies to better characterize the determinants and consequences of polypharmacy in cancer cohorts.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},363479,1790375288,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":36,"preview_page_count":19,"preview_urls":150},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Tawengi etal. Systematic Reviews (2026) 15:176 [https://doi.org/10.1186/s13643-026-03068-2](https://doi.org/10.1186/s13643-026-03068-2)  \nSystematic Reviews  \n RESEARCH Open Access  \nPrevalence and determinants  \nof polypharmacy among cancer patients: a systematic review and meta-analysis  \nMohamed M. Tawengi 1,2†, Jawaher Baraka1,2†, Rafal Al Shibly1† and Mohammed I. Danjuma 1,2,3,4*  \nAbstract  \nBackground Polypharmacy (PP) is a rising clinical challenge among patients with a cancer diagnosis. Uncertainty remains regarding its exact burden, exact prevalence estimates, and definitional themes in this vulnerable cohort of patients.  \nMethods We searched PubMed, EMBASE, Scopus, the Cochrane Database of Systematic Reviews (CDSR), and Google Scholar, for studies published between 2000 and 2025 for eligible studies reporting on polypharmacy in cancer patients. These were critically appraised for eligibility and inclusion by two independent reviewers. Using quality and random effect models, pooled estimates of the prevalence of PP, prevalence by type of cancer, and geographical spread were determined. The prevalence rates of potentially inappropriate medications (PIMs) and drug-drug interactions (DDIs) were also estimated. Heterogeneity among the included studies was reported by corresponding I2 estimates.  \nResults This meta-analytical review involved 20 studies comprising (n= 102,100) participants. The overall pooled prevalence of polypharmacy among patients with cancer was 29%(95% CI 10–52%) using the quality effects model, and 58%(95% CI 50–62%) using the random effects model. The overall heterogeneity among the included studies was significant (I2 = 100%, p \u003C 0. 001) for the random effects models.  \nConclusion From this meta-analysis of studies with diverse designs, we found a high pooled prevalence of polypharmacy among patient cohorts with cancer, with marked variability across studies. Given this level of heterogeneity, future prospective and systematic studies are needed to better characterize the determinants and consequences of polypharmacy to guide strategies that may improve patient outcomes in these cohorts.  \nSystematic review registration PROSPERO, Number CRD42024576772 .  \nKeywords Polypharmacy, Cancer, Epidemiology, Systematic review, Meta-analysis  \n†Mohamed M. Tawengi, Jawaher Baraka and Rafal Al Shibly contributed equally to this work.  \n*Correspondence: Mohammed I. Danjuma  \n[mdanjuma@hamad.qa](mdanjuma@hamad.qa); [mdanjuma21@gmail.com](mdanjuma21@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026, modified publication 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nTawengi etal. Systematic Reviews (2026) 15:176  \nBackground  \nPolypharmacy is a prescribing practice associated with adverse outcomes [1]. Polypharmacy (PP) has generated and continues to generate increasing concerns among ","cbCaik2klVeQzK8a","https://ap.wps.com/l/cbCaik2klVeQzK8a","pdf",2751032,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n## Definition and prevalence variability\n## Potential mechanisms and clinical implications","[{\"question\":\"What does the study aim to determine about polypharmacy in cancer patients?\",\"answer\":\"It estimates the overall prevalence of polypharmacy, explores prevalence by type of cancer, and evaluates related patterns such as potentially inappropriate medications and drug–drug interactions.\"},{\"question\":\"Which databases and time period were searched?\",\"answer\":\"PubMed, EMBASE, Scopus, CDSR, and Google Scholar were searched for studies published between 2000 and 2025.\"},{\"question\":\"What prevalence range was found across the included studies?\",\"answer\":\"The pooled prevalence was 29% (95% CI 10–52%) under the quality effects model and 58% (95% CI 50–62%) under the random effects model, with substantial heterogeneity reported (I2 = 100%).\"},{\"question\":\"Why does the study emphasize further research?\",\"answer\":\"Marked variability and high heterogeneity indicate the need for future prospective and systematic studies to better characterize the determinants and consequences of polypharmacy in cancer cohorts.\"}]","Prevalence and determinants of polypharmacy among cancer patients - a systematic review and meta-analysis | PDF",1790151416,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eb1948f041e11252374b5b4b8b50610.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8940b9b434ad0b1f21901721bae13c94.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de9ed51d02ea78e3641fac9c0c1bddd5.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85f950986ca204a2ba15d63258b2e8c6.webp",980,1301]